Antimicrobial Agents Practice Questions

Q: Which of the following antiretroviral drugs is a non-nucleoside reverse transcriptase inhibitor?

Efavirenz. ### Explanation **Correct Answer: B. Efavirenz** **Mechanism and Classification:** Antiretroviral therapy (ART) is classified based on the stage of the HIV life cycle the drugs inhibit [2]. **Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)** like **Efavirenz** bind directly and non-competitively to the enzyme reverse transcriptase at a site distinct from the active site (allosteric site). This induces a conformational change that inhibits the conversion of viral RNA to DNA. Unlike NRTIs, NNRTIs do not require intracellular phosphorylation to become active. **Analysis of Incorrect Options:** * **A. Zidovudine (AZT) & D. Stavudine (d4T):** These are **Nucleoside Reverse Transcriptase Inhibitors (NRTIs)** [3]. They act as competitive inhibitors and "chain terminators" [1]. They are structural analogs of native nucleosides and must be phosphorylated by host cell kinases into triphosphate forms to be active [1]. * **C. Saquinavir:** This is a **Protease Inhibitor (PI)** [3]. It inhibits the viral protease enzyme, preventing the cleavage of precursor polyproteins (gag-pol), which results in the production of immature, non-infectious virions [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Efavirenz Side Effects:** Characteristically causes **CNS side effects** (vivid dreams, nightmares, dizziness, and "hangover" feeling). It is also associated with **teratogenicity** (neural tube defects), though recent guidelines have relaxed restrictions in pregnancy. * **Nevirapine (another NNRTI):** Known for causing severe hepatotoxicity and Stevens-Johnson Syndrome (SJS) [4]. It was historically used to prevent mother-to-child transmission (MTCT). * **Mnemonic for NNRTIs:** "**DEN**" – **D**elavirdine, **E**favirenz, **N**evirapine (and newer agents like Etravirine and Rilpivirine). * **Zidovudine** is specifically known for causing **bone marrow suppression** (anemia/neutropenia).

Q: Which of the following can be given as a single dose antimalarial for P.vivax malaria?

Pyrimethamine + Sulfadoxime. **Explanation:** The combination of **Pyrimethamine and Sulfadoxime (S/P)** is characterized by an exceptionally long half-life (Sulfadoxime ~7–9 days; Pyrimethamine ~4 days). This pharmacological profile allows for **single-dose administration**, ensuring high patient compliance. It acts via sequential blockade of folic acid synthesis, targeting the erythrocytic schizonts of malaria parasites. While primarily used for *P. falciparum*, it is also effective against the erythrocytic stages of *P. vivax*. **Analysis of Incorrect Options:** * **A. Atovaquone + Proguanil:** This combination (Malarone) requires a **3-day course** for treatment or daily administration for prophylaxis. It is not used as a single dose. * **B. Artemisinin:** Artemisinin derivatives (like Artesunate or Artemether) have very short half-lives. When used as monotherapy, they require at least 5–7 days of treatment; in ACT (Artemisinin-based Combination Therapy), they are typically given for **3 days**. * **C. Quinine + Tetracycline:** Quinine has a short half-life and narrow therapeutic index, requiring dosing every 8 hours for **7 days**. Tetracycline also requires a 7-day course. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** S/P inhibits Dihydrofolate Reductase (Pyrimethamine) and Dihydropteroate Synthase (Sulfadoxime). * **Radical Cure:** Note that while S/P treats the blood stage of *P. vivax*, a **14-day course of Primaquine** (or a single dose of **Tafenoquine**) is mandatory to clear the **hypnozoites** (liver stage) and prevent relapse. * **Contraindication:** Avoid S/P in patients with sulfa allergies or severe renal/hepatic failure. It is also avoided in the first trimester of pregnancy due to antifolate effects.

Q: Which of the following is NOT included in the treatment of Mycobacterium avium complex?

Pyrazinamide. **Explanation:** The **Mycobacterium avium complex (MAC)** consists of *M. avium* and *M. intracellulare*. Unlike *Mycobacterium tuberculosis*, MAC is **intrinsically resistant** to most standard first-line antitubercular drugs, most notably **Pyrazinamide**. 1. **Why Pyrazinamide (D) is the correct answer:** Pyrazinamide requires an acidic environment and the enzyme pyrazinamidase to be converted into its active form (pyrazinoic acid). MAC lacks the specific susceptibility mechanisms required for Pyrazinamide to be effective; therefore, it has no role in the treatment of MAC infections. 2. **Why the other options are incorrect:** * **Clarithromycin (B):** Macrolides (Clarithromycin or Azithromycin) are the **cornerstone** of MAC therapy. They inhibit protein synthesis and are essential for both prophylaxis and treatment. * **Rifabutin (C):** This is a rifamycin preferred over Rifampin for MAC because it is more potent against this complex and has fewer drug-drug interactions in HIV patients on HAART. * **Ciprofloxacin (A):** Fluoroquinolones (like Ciprofloxacin or Moxifloxacin) are considered **second-line or adjunctive agents** used in multidrug regimens for macrolide-resistant MAC or disseminated disease. **High-Yield Clinical Pearls for NEET-PG:** * **Standard Regimen for MAC:** Clarithromycin + Ethambutol + Rifabutin. * **Prophylaxis:** In HIV patients with **CD4 counts <50 cells/mm³**, primary prophylaxis with Azithromycin or Clarithromycin is indicated. * **Key Distinction:** Pyrazinamide is only used for *M. tuberculosis*; it is ineffective against almost all Non-Tuberculous Mycobacteria (NTM).

Q: Which of the following antibiotics is not used in the treatment of enterococcal infections?

Cephalexin. **Explanation:** The correct answer is **Cephalexin (Option D)**. The fundamental pharmacological concept to remember for NEET-PG is that **Enterococci are inherently resistant to all Cephalosporins.** This is due to the low affinity of enterococcal Penicillin-Binding Proteins (PBPs), specifically PBP5, for cephalosporins. Therefore, regardless of the generation, cephalosporins (like Cephalexin, a 1st generation agent) are never used to treat enterococcal infections. **Analysis of Options:** * **Vancomycin (Option A):** A glycopeptide that is traditionally the drug of choice for serious ampicillin-resistant enterococcal infections. It inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus. * **Linezolid (Option B):** An oxazolidinone used primarily for Vancomycin-Resistant Enterococci (VRE). It inhibits protein synthesis by binding to the 50S ribosomal subunit. * **Teicoplanin (Option C):** Another glycopeptide similar to Vancomycin. It is effective against many strains of *Enterococcus faecalis* and *E. faecium*, though some VRE strains (VanA phenotype) are also resistant to it. **High-Yield Clinical Pearls for NEET-PG:** 1. **LAME mnemonic:** Cephalosporins lack activity against **L**isteria, **A**typicals (Mycoplasma/Chlamydia), **M**RSA (except Ceftaroline), and **E**nterococci. 2. **Synergy:** For serious enterococcal infections (e.g., endocarditis), an aminoglycoside (Gentamicin) is added to a cell-wall active agent (Ampicillin or Vancomycin) for bactericidal synergy. 3. **Drug of Choice:** For uncomplicated *E. faecalis*, **Ampicillin** remains the first-line treatment. For VRE, **Linezolid** or **Daptomycin** are preferred.

Q: A 29-year-old female diagnosed with AIDS presents with progressive blurring of vision in her right eye. Fundoscopic examination reveals a small, white, opaque lesion on the retina. What is the most appropriate therapy for this patient?

Ganciclovir. The clinical presentation of progressive blurring of vision and a white, opaque retinal lesion in a patient with AIDS is highly suggestive of **CMV Retinitis**. This is the most common opportunistic ocular infection in HIV-infected individuals, typically occurring when the CD4 count falls below 50 cells/mm³ [1, 2]. **1. Why Ganciclovir is Correct:** Ganciclovir is the first-line treatment for CMV infections [1, 2]. It is a guanosine analogue that requires initial phosphorylation by a viral protein kinase (**UL97**) to ganciclovir monophosphate, followed by conversion to the triphosphate form by host cell kinases. This active form competitively inhibits viral DNA polymerase, terminating CMV DNA synthesis. **2. Why Other Options are Incorrect:** * **Acyclovir:** Primarily used for HSV and VZV. It is ineffective against CMV because CMV lacks the viral thymidine kinase required to activate acyclovir. * **Amantadine:** An antiviral agent used for Influenza A (by inhibiting the M2 ion channel) and Parkinson’s disease. It has no activity against DNA viruses like CMV. * **Flucytosine:** An antifungal agent used in combination with Amphotericin B for Cryptococcal meningitis. It has no antiviral properties. **High-Yield Clinical Pearls for NEET-PG:** * **CMV Retinitis Appearance:** Often described as "pizza-pie" or "cottage cheese and ketchup" appearance (hemorrhage with exudates). * **Side Effects:** The dose-limiting toxicity of Ganciclovir is **bone marrow suppression** (neutropenia, thrombocytopenia). * **Alternative Drugs:** If Ganciclovir resistance occurs (UL97 mutation), **Foscarnet** or **Cidofovir** are used; these do not require viral phosphorylation for activation [3]. * **Valganciclovir:** The oral prodrug of ganciclovir, often used for maintenance therapy [3].

Q: Which of the following is NOT a NNRTI?

Ritonavir. The correct answer is **Ritonavir** because it belongs to the **Protease Inhibitor (PI)** class of antiretroviral therapy (ART), not the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) class. ### **Explanation of Options** * **Ritonavir (Option A):** This is a Protease Inhibitor. In modern clinical practice, it is primarily used as a **"pharmacokinetic enhancer" (booster)**. It inhibits the CYP3A4 enzyme, thereby increasing the plasma concentrations and half-life of other protease inhibitors (like Lopinavir or Atazanavir). * **Nevirapine (Option B):** A first-generation NNRTI. It is well-known for its role in preventing mother-to-child transmission of HIV, though it is associated with a high risk of hepatotoxicity and severe skin rashes (Stevens-Johnson Syndrome). * **Efavirenz (Option C):** A first-generation NNRTI. It is a high-yield topic due to its unique side effect profile, including **neuropsychiatric symptoms** (vivid dreams, insomnia, psychosis) and potential teratogenicity (neural tube defects). * **Delavirdine (Option D):** A first-generation NNRTI. It is less commonly used in clinical practice today but remains a classic textbook example of the NNRTI class. ### **High-Yield Clinical Pearls for NEET-PG** 1. **Mechanism of Action:** NNRTIs bind to a **hydrophobic pocket** (allosteric site) on the HIV-1 Reverse Transcriptase enzyme, causing a conformational change. Unlike NRTIs, they do *not* require phosphorylation to become active and do *not* compete with nucleosides. 2. **Class Specificity:** NNRTIs are active only against **HIV-1**, whereas NRTIs and PIs are active against both HIV-1 and HIV-2. 3. **Second Generation NNRTIs:** Remember **Etravirine** and **Rilpivirine**; these are often used when resistance develops to first-generation agents. 4. **Mnemonic for NNRTIs:** "The **NED** family" (**N**evirapine, **E**favirenz, **D**elavirdine).

Q: Clavulanic acid is given in combination with amoxicillin in order to:

Extend amoxicillin's antibacterial spectrum. **Explanation:** The correct answer is **D. Extend amoxicillin's antibacterial spectrum.** **Mechanism of Action:** Amoxicillin is a beta-lactam antibiotic that is susceptible to degradation by **beta-lactamase enzymes** produced by certain bacteria (e.g., *Staphylococcus aureus*, *H. influenzae*, and *E. coli*). Clavulanic acid is a **"suicide inhibitor"** of beta-lactamase. It has negligible antibacterial activity of its own but binds irreversibly to the beta-lactamase enzyme, protecting amoxicillin from destruction. This allows amoxicillin to inhibit bacterial cell wall synthesis in organisms that would otherwise be resistant, thereby effectively **extending its spectrum** to include beta-lactamase-producing strains. **Analysis of Incorrect Options:** * **A. Reduce allergic reactions:** Clavulanic acid does not modulate the immune system; hypersensitivity reactions (Type I-IV) are inherent to the penicillin structure itself. * **B. Prolong half-life:** The half-life of amoxicillin is determined by renal excretion. Clavulanic acid does not interfere with the renal tubular secretion of amoxicillin (unlike Probenecid, which does). * **C. Reduce diarrhea:** In fact, the combination (Co-amoxiclav) is **more likely** to cause diarrhea and GI upset than amoxicillin alone, as clavulanic acid increases gut motility. **High-Yield NEET-PG Pearls:** * **Other Beta-lactamase Inhibitors:** Sulbactam (paired with Ampicillin) and Tazobactam (paired with Piperacillin). * **Suicide Inhibition:** Clavulanic acid is the classic example where the inhibitor is chemically modified by the enzyme during the process of inhibition. * **Clinical Note:** Co-amoxiclav is a notorious cause of **drug-induced cholestatic jaundice**, a side effect specifically attributed to the clavulanate component.

Q: In cotrimoxazole, what is the ratio of sulphamethoxazole to trimethoprim?

5:1. The original explanation provided the answer details without citations. **Cotrimoxazole** is a fixed-dose combination of **Sulphamethoxazole (SMZ)** and **Trimethoprim (TMP)**. [1] The correct ratio in the formulation is **5:1** (e.g., 400 mg SMZ + 80 mg TMP). [3] **1. Why 5:1 is the Correct Answer:** While both drugs act on the same metabolic pathway (folic acid synthesis), they have different pharmacokinetic profiles. [1] Trimethoprim is significantly more lipid-soluble and has a larger volume of distribution than Sulphamethoxazole. To achieve the **optimal synergistic plasma concentration ratio of 20:1** (which is required for maximum bactericidal effect), the drugs must be administered in a **5:1 dose ratio**. [3] This compensates for the difference in their distribution and clearance rates. [4] **2. Analysis of Incorrect Options:** * **A (2:1) & B (1:1):** These ratios would result in insufficient plasma levels of Trimethoprim relative to Sulphamethoxazole, failing to reach the 20:1 steady-state plasma concentration needed for synergy. * **D (4:5):** This is mathematically incorrect and does not align with any standard pharmacological preparation of these agents. [3] **3. NEET-PG High-Yield Clinical Pearls:** * **Mechanism of Action:** Sequential blockade of folate synthesis. [2] SMZ inhibits *Dihydropteroate synthase*, while TMP inhibits *Dihydrofolate reductase*. [1] * **Nature of Action:** Individually, both drugs are bacteriostatic; in combination (Cotrimoxazole), they become **bactericidal**. [2][3] * **Drug of Choice (DOC):** Cotrimoxazole remains the DOC for *Pneumocystis jirovecii* pneumonia and *Stenotrophomonas maltophilia*. [3] * **Adverse Effects:** Watch for Megaloblastic anemia (due to folate deficiency) and Stevens-Johnson Syndrome (due to the sulfonamide component). [3]

Q: Which drug is known to produce Stevens-Johnson syndrome in HIV-infected individuals?

Thioacetazone. **Explanation:** **Thioacetazone** is a bacteriostatic second-line anti-tubercular drug. The correct answer is C because Thioacetazone is notorious for causing severe, life-threatening cutaneous adverse drug reactions (CADR), specifically **Stevens-Johnson Syndrome (SJS)** and **Toxic Epidermal Necrolysis (TEN)**, in patients with HIV co-infection. The risk is significantly higher in this population due to altered immune responses and glutathione deficiency. Consequently, the WHO and national guidelines (including NTEP) strictly contraindicate the use of Thioacetazone in HIV-positive individuals. **Analysis of Incorrect Options:** * **A. Paraaminosalicylate (PAS):** Primarily causes gastrointestinal distress (nausea, vomiting, diarrhea) and hypersensitivity reactions like skin rashes or drug-induced hepatitis, but it is not specifically linked to SJS in HIV patients. * **B. Cycloserine:** Known for its **neuropsychiatric side effects** (the "psych-drug"), including seizures, psychosis, and depression. It does not typically cause severe cutaneous reactions. * **D. Rifampicin:** Commonly causes a harmless orange discoloration of body fluids (urine, sweat, tears) and hepatotoxicity. While it can cause "flu-like syndrome," it is not the primary culprit for SJS in the context of HIV. **High-Yield Clinical Pearls for NEET-PG:** * **Thioacetazone Rule:** Never prescribe Thioacetazone to a patient unless their HIV status is confirmed negative. * **Other SJS Culprits in HIV:** Apart from Thioacetazone, **Nevirapine** (an NNRTI) and **Sulfonamides** (like Cotrimoxazole) are the most common causes of SJS in HIV-infected individuals. * **Mechanism:** Thioacetazone inhibits mycolic acid synthesis (similar to Isoniazid) but is rarely used today due to its toxicity profile.

Question 1

A 65-year-old male with pneumonia has a sputum culture positive for a staphylococcal strain that is 
-lactamase-positive. Which is the best choice of penicillin therapy in this patient?

Accepted Answer

Oxacillin

Answer

Ampicillin

Answer

Ticarcillin

Answer

Penicillin G

Question 2

Which of the following antiretroviral drugs is a non-nucleoside reverse transcriptase inhibitor?

Accepted Answer

Efavirenz

Answer

Zidovudine

Answer

Saquinavir

Answer

Stavudine

Question 3

Which of the following can be given as a single dose antimalarial for P.vivax malaria?

Accepted Answer

Pyrimethamine + Sulfadoxime

Answer

Atovaquone + Proguanil

Answer

Artemisinin

Answer

Quinine + Tetracycline

Question 4

Which of the following is NOT included in the treatment of Mycobacterium avium complex?

Accepted Answer

Pyrazinamide

Answer

Ciprofloxacin

Answer

Clarithromycin

Answer

Rifabutin

Question 5

Which of the following antibiotics is not used in the treatment of enterococcal infections?

Accepted Answer

Cephalexin

Answer

Vancomycin

Answer

Linezolid

Answer

Teichoplanin

Question 6

A 29-year-old female diagnosed with AIDS presents with progressive blurring of vision in her right eye. Fundoscopic examination reveals a small, white, opaque lesion on the retina. What is the most appropriate therapy for this patient?

Accepted Answer

Ganciclovir

Answer

Acyclovir

Answer

Amantadine

Answer

Flucytosine

Question 7

Which of the following is NOT a NNRTI?

Accepted Answer

Ritonavir

Answer

Nevirapine

Answer

Efavirenz

Answer

Delavirdine

Question 8

Clavulanic acid is given in combination with amoxicillin in order to:

Accepted Answer

Extend amoxicillin's antibacterial spectrum

Answer

Reduce the risk of allergic reactions

Answer

Prolong amoxicillin's half-life

Answer

Reduce the severity of diarrhea

Question 9

In cotrimoxazole, what is the ratio of sulphamethoxazole to trimethoprim?

Accepted Answer

5:1

Answer

2:1

Answer

1:1

Answer

4:5

Question 10

Which drug is known to produce Stevens-Johnson syndrome in HIV-infected individuals?

Accepted Answer

Thioacetazone

Answer

Paraaminosalicylate

Answer

Cycloserine

Answer

Rifampicin

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?